Vapotherm, Inc. announced the debut of its Access365? Home Ventilation Solution at the upcoming MEDTRADE conference. The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th.

The device is designed to reduce hospital readmissions, improve patient quality of life, and reduce HME costs for late-stage hypercapnic COPD patients. In addition to VAPS and volume control/assist ventilation modes and Vapotherm's proven high velocity therapy, the ventilator incorporates a built-in medical grade humidifier and integrated Bluetooth pulse oximetry and spirometry. The Access365 Home Ventilation Solution also includes cloud connectivity to enable remote data retrieval and system upgrades and a patient engagement platform which breaks the cycle of symptom exacerbation and readmission through early identification of worsening symptoms allowing more rapid clinical intervention.

This proprietary algorithm resulted in up to a 41% reduction in late-stage COPD hospital readmissions. Vapotherm anticipates receiving FDA clearance for Access365 in early 2025.